Estonia vs Maldives: The number of people with susceptibility test result for rifampicin
Estonia
96.1
in 2021
Maldives
95.83
in 2021
Estonia rank
48th
Maldives rank
50th
The number of people with susceptibility test result for rifampicin over time
- Estonia
- Maldives
How they compare
Estonia currently reports 96.1 against 95.83 in Maldives, a difference of 0.27.
Across all 5 years both countries report, Estonia has been ahead every year.
Estonia ranks 48th and Maldives ranks 50th of 146 countries.
Estonia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Estonia | Maldives | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 99.41 | 71.76 | 27.66 | Estonia |
| 2020s | 95.95 | 79.08 | 16.87 | Estonia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Estonia or Maldives?
- Estonia, at 96.1 against 95.83 in Maldives as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Estonia and Maldives?
- 0.27, with Estonia ahead.
- How many years of comparable data are there for Estonia and Maldives?
- 5 years are reported by both, from 2017 to 2021.
- How do Estonia and Maldives rank globally for the number of people with susceptibility test result for rifampicin?
- Estonia ranks 48th and Maldives ranks 50th of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.